Provided by Tiger Trade Technology Pte. Ltd.

Serina Therapeutics, Inc.

2.57
+0.07002.80%
Post-market: 2.56-0.0100-0.39%19:59 EDT
Volume:404.46K
Turnover:1.05M
Market Cap:65.28M
PE:-1.33
High:2.78
Open:2.75
Low:2.35
Close:2.50
52wk High:5.83
52wk Low:1.22
Shares:25.40M
Float Shares:11.48M
Volume Ratio:11.26
T/O Rate:3.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9304
EPS(LYR):-1.9100
ROE:-207.94%
ROA:-92.30%
PB:3.49
PE(LYR):-1.35

Loading ...

Serina Therapeutics Inc: Reports Cohort 1 Observations from Ser-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

THOMSON REUTERS
·
Yesterday

Serina Therapeutics - Expects to Report Topline Data from the Single-Ascending-Dose Portion of the Study in First Half of 2027

THOMSON REUTERS
·
Yesterday

Serina Therapeutics - Blinded Cohort 1 Observations Showed Pharmacokinetic Profile Consistent with Sustained Apomorphine Exposure Ser-252

THOMSON REUTERS
·
Yesterday

Serina Therapeutics Advances SER-252 Parkinson’s Registrational Study to Cohort 2 After Safety Review

Reuters
·
Yesterday

Serina Therapeutics Signs Deal for up to USD 25 Million Unregistered Common Stock Sales to Roth Principal Investments

Reuters
·
Aug 27

Serina Therapeutics - Enters Stock Purchase Agreement with Roth Principal Investments on Aug 21, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 27

Serina Therapeutics - Offers up to 12,500,000 Shares of Common Stock by Roth Principal Investments - SEC Filing

THOMSON REUTERS
·
Aug 25

Serina Therapeutics: Buy Rating Reiterated, $11 Price Target Maintained on Strong SER-252 Clinical Progress

TIPRANKS
·
Aug 19

Serina Therapeutics, Inc Q2 Operating Expenses USD 6.784 Million

THOMSON REUTERS
·
Aug 14

Serina Therapeutics Q2 FY26 Net Loss Narrows to $6.36 Million; Revenue Falls to no Grant Revenue

Reuters
·
Aug 14

Serina Therapeutics Posts Investor Deck Outlining POZ Platform, Lead Parkinson’s Candidate Ser-252 Phase 1b Study

Reuters
·
Jul 29

Serina Therapeutics to Join BTIG Virtual Biotechnology Conference Investor Meetings

Reuters
·
Jul 24

Serina Therapeutics Director Simon Farrell Files Initial Beneficial Ownership Statement

Reuters
·
Jul 24

Serina Therapeutics CEO Steve Ledger Base Salary Rises to $500,000 Under Amended Employment Deal

Reuters
·
Jul 24

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of Ser-252 for Advanced Parkinson’s Disease

THOMSON REUTERS
·
Jul 23

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

GlobeNewswire
·
Jul 23

Serina Therapeutics Appoints Trevi CCO Farrell Simon to Board

Reuters
·
Jul 23

Serina Therapeutics Appoints Farrell Simon to Its Board of Directors

THOMSON REUTERS
·
Jul 23

Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease

MT Newswires Live
·
Jul 10

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1B Registrational Trial of Ser-252 for Advanced Parkinson’s Disease

THOMSON REUTERS
·
Jul 10